Research progress of immunotherapy in ovarian cancer

赵海云; 吴小华

doi:10.19401/j.cnki.1007-3639.2020.07.009

您当前的位置：

首页 >

文章列表页 >

Research progress of immunotherapy in ovarian cancer

更新时间：2026-01-27

- Research progress of immunotherapy in ovarian cancer
- China Oncology Vol. 30, Issue 7, Pages: 538-545(2020)
- 作者机构：
  
  复旦大学附属肿瘤医院妇瘤科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2020.07.009
  CLC： R737.31
- Published Online：06 August 2020，
  
  Published：06 August 2020
- 稿件说明：
移动端阅览
赵海云, 吴小华. 免疫治疗在卵巢癌中的应用研究进展[J]. 中国癌症杂志, 2020, 30(7): 538-545.

赵海云, 吴小华. Research progress of immunotherapy in ovarian cancer[J]. China Oncology, 2020, 30(7): 538-545.
赵海云, 吴小华. 免疫治疗在卵巢癌中的应用研究进展[J]. 中国癌症杂志, 2020, 30(7): 538-545. DOI： 10.19401/j.cnki.1007-3639.2020.07.009.

赵海云, 吴小华. Research progress of immunotherapy in ovarian cancer[J]. China Oncology, 2020, 30(7): 538-545. DOI： 10.19401/j.cnki.1007-3639.2020.07.009.

摘要

卵巢癌的临床早期症状不明显，筛查手段有限，就诊时常处于晚期阶段，5年生存率仅30%~45%，严重威胁着女性健康。免疫治疗尤其是免疫检查点抑制剂治疗因其持久的抗肿瘤效应已被批准用于晚期或复发性的多种类型癌症的治疗。目前免疫治疗的一些研究进展为卵巢癌患者的临床管理提供了新的机遇与挑战。

Abstract

Five-year survival of ovarian cancer is 30%-45% for its non-obvious clinical symptoms

limited screening methods and advanced stage at initial diagnosis

which seriously threatens the health of women. Immunotherapy

especially immune checkpoint blockade

has been approved for treatment for patients with metastatic or recurrent multiple cancers for its durable anti-tumor effect. Also

the research progress of immunotherapy provides clinical management of ovarian cancer patients with new opportunities and challenges.

关键词

Keywords

references

Views

3521

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The latest progress and prospect of gynecological tumor treatment at 2023 ESMO

Targeted therapy and immunotherapy combined with chemotherapy bring effective response to AFP positive colon cancer patients: a case report and literature review

Mechanism study of MYC promoting proliferation and metastasis in prostate cancer by targeting CD47

MDT consensus on immunotherapy for locally advanced head and neck squamous cell carcinoma (2025 edition)

Research status and progress of third-line treatment for metastatic colorectal cancer

Related Author

Lingfang XIA

Jun ZHU

Xiaohua WU

LIU Miao

LI Jinze

WU Chensi

ZHANG Fengbin

GAO Hongsheng

Related Institution

Department of Gynecological Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Gastroenterology, the Fourth Hospital of Hebei Medical University

Department of Pathology, the Fourth Hospital of Hebei Medical University

College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology

Department of Urology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology

AI问答

⁰